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Abstract. The aqueous photochemistry of cis-[Ru(bpy)2(CO)Cl]
+
 (1) was investigated at 310 
K and under visible light (white) irradiation by NMR and ESI-HR-MS. Complex 1 releases a 
Cl ligand, coordinates a solvent molecule and forms the complex cis-[Ru(bpy)2(CO)(H2O)]
2+
 
(2). Also, irradiation experiments were performed in the presence of the nucleobase 
derivatives 9-ethylguanine (9-EtG) and 9-ethyladenine (9-EtA). Formation of Ru-9-EtG 
adducts was observed after 3 h irradiation by NMR and HR-MS, while only very small 
amounts of a Ru-9-EtA adduct could be detected by HR-MS. Solution structural data were 
obtained by X-ray absorption spectroscopy (XAS) for both 1 and 2. EXAFS gave a Ru–Cl 
distance of 2.416(7) Å for 1, and a Ru–OH2O distance of 2.102(6) Å for 2. DFT and TDDFT 
were employed to study the photophysical and photochemical properties of 1. Calculations 
show that dissociative metal-centered states can be related to the light-induced release of a Cl 
ligand and subsequent coordination of a solvent molecule. The compound showed no 
antiproliferative activity in three human carcinoma cell lines (lung, bladder, pancreas) under 
the testing conditions, either with or without irradiation with UV-light. 
 
Introduction 
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Ruthenium bipyridyl complexes are well known for their photophysical and photochemical 
properties, which have been successfully exploited for biomedical and biophysical 
applications.
1
 In particular, their absorption and emission features have been used to 
investigate the ability of these ruthenium derivatives to interact with bio-macromolecules, 
such as proteins and DNA.
2
 
Furthermore, ruthenium complexes show potential as alternatives to platinum derivatives in 
chemotherapy
3
 and two ruthenium(III) complexes, namely NAMI-A
3a,4
 and KP1019,
5
 are on 
clinical trial. Several Ru(II) bipyridyl complexes have been studied as possible anticancer 
agents as well. A number of studies indicate that the most lipophillic molecules are often the 
most cytotoxic and that DNA does not seem to be a target for this family of compounds. 
Confocal microscopy highlights that ruthenium(II) bipyridyl dyes do not accumulate in the 
nucleus, and that their cellular uptake occurs either by endocytosis or by active transport, 
depending on the structure of the complex.
6
 In the case of E. coli the outer membrane protein 
OMPF appears to be involved in the transportation of polypyridyl ruthenium complexes into 
the cells.
7
 However, a few cases in which ruthenium polypyridyl complexes are able to bind 
DNA or DNA bases have been reported.
8
 Among these, [Ru(bpy)2Cl2] (where bpy = 2,2′-
bipyridine) was found to be inactive towards murine and human tumor cell lines, while 
[Ru(terpy)Cl3] (where terpy = 2,2′;6′,2′′-terpyridine) showed remarkably high cytotoxicity.
9
 
To explore further the promising field of metal-based photochemotherapy,
10
 we have recently 
investigated the design of new photoactivable ruthenium complexes.
11
 When irradiated with 
visible light, these are able to release a coordinated ligand and form a reactive aqua species 
which can subsequently bind to DNA bases. Due to their rich photochemistry and synthetic 
versatility, ruthenium bipyridyl complexes are strong candidates for designing new anticancer 
prodrugs that can be activated by light excitation. The photoproducts can display different 
reactivity and cell distribution properties compared to ground-state metal complexes 
(prodrugs), and therefore light activation can be employed to extend the variety of bio-
macromolecules targeted by this class of complexes.
4,12
 Also photoactivation is able to limit 
the effects of cytotoxic species to irradiated areas, thus allowing specific tissues to be 
targeted within an organism. 
In this study we describe the structural, photochemical and nucleobase binding properties of 
the ruthenium carbonyl complex cis-[Ru(bpy)2(CO)Cl]
+
 (1). Complex 1 has been previously 
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studied as a photocatalyst for the water gas shift reaction
13
 and for CO2 photoreduction.
14
 
Although there has been some disagreement
13,14,16a
 on the species formed by light excitation 
of cis-[Ru(bpy)2(CO)Cl]
+
, we found that 1 is able to dissociate one Cl
–
 and form the aqua 
photoproduct cis-[Ru(bpy)2(CO)(H2O)]
2+
 (2), Scheme 1.
13
 Detailed investigations of the 
structural and electronic properties of 1 and 2 using a variety of techniques (NMR, IR, MS, 
UV-visible, XAS and DFT calculations) were carried out to elucidate the mechanism of 
ligand photodissociation from 1. Nucleobase binding experiments with 9-ethylguanine (9-
EtG) and 9-ethyladenine (9-EtA) using NMR and mass spectrometry both in the dark and 
under irradiation were performed to investigate whether complex 1 might be a candidate for 
photoactivated targeting of DNA in cells. 
 
Experimental Section 
Materials. All solvents and reagents in the synthetic procedures were of analytical/reagent 
grade and used as received. Ruthenium(III) chloride hydrate was purchased from Lancaster. 
Lithium chloride, sodium perchlorate, 9-ethylguanine and 9-ethyladenine were purchased 
from Aldrich and used without further purification. 2,2′-bipyridine, obtained from Aldrich, 
was purified by crystallization from hexane.
15
 
Synthesis of cis-[Ru(bpy)2(CO)Cl]ClO4, [1(ClO4)]. Cis-[Ru(bpy)2(CO)Cl]ClO4, was 
prepared according to slightly modified literature methods.
16
 A solution of ruthenium(III) 
chloride trihydrate (10 g, 38.2 mmol), 2,2′-bipyridine (12 g, 76.9 mmol) and LiCl (11 g) in 
N,N-dimethylformamide (60 mL) was refluxed for 8 h under N2. After cooling at room 
temperature, the solution was poured rapidly into stirring acetone (300 mL). The resulting 
mixture was allowed to stand at 273 K overnight. The resultant dark green microcrystalline 
material, cis-[Ru(bpy)2Cl2], was collected on a sintered-glass filter. Complex 1 was obtained 
by adding sodium perchlorate (1 g) to the mother liquor remaining after the removal of cis-
[Ru(bpy)2Cl2]. The product was filtered and washed with aliquots of a saturated aqueous 
solution of sodium perchlorate, and then with water (6.6 g, 11.5 mmol, 30% yield based on 
the ruthenium(III) chloride trihydrate starting material). 
1
H NMR (D2O 95%/dmso-d6 5%, ppm) δ: 7.36 (t, 
3
JHH = 5.9 Hz, 1H), 7.53 (t, 
3
JHH = 6.4 Hz, 
1H), 7.65 (d, 
3
JHH = 5.0 Hz, 1H), 7.77 (d, 
3
JHH = 5.9 Hz, 1H), 7.89 (t, 
3
JHH = 7.8 Hz, 1H), 7.97 
(t, 
3
JHH = 6.4 Hz, 1H), 8.11 (t, 
3
JHH = 7.8 Hz, 1H), 8.23 (t, 
3
JHH = 7.8 Hz, 1H), 8.34 (t, 
3
JHH = 
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7.8 Hz, 1H), 8.45 (t, 
3
JHH = 7.6 Hz, 1H), 8.48 (d, 
3
JHH = 8.2 Hz, 1H), 8.61 (d, 
3
JHH = 8.3 Hz, 
1H), 8.64 (d, 
3
JHH = 8.6 Hz, 1H), 8.66 (d, 
3
JHH = 7.6 Hz, 1H), 9.41 (d, 
3
JHH = 5.0 Hz, 1H), 
9.50 (d, 
3
JHH = 5.7 Hz, 1H). 
1
H NMR (CD2Cl2, ppm) δ: 7.35 (t, 
3
JHH = 6.7 Hz, 1H), 7.41–7.45 
(m, 2H), 7.67 (d, 
3
JHH = 4.4 Hz, 1H), 7.71 (td, 
3
JHH = 6.7 Hz, 1H), 7.81 (td, 
3
JHH = 6.6 Hz, 
1H), 8.04 (td, 
3
JHH = 7.9 Hz, 1H), 8.09 (td, 
3
JHH = 7.4 Hz, 1H), 8.18 (td, 
3
JHH = 7.9 Hz, 1H), 
8.31 (td, 
3
JHH = 7.9 Hz, 1H), 8.36 (d, 
3
JHH = 8.1 Hz, 1H), 8.37 (d, 
3
JHH = 7.8 Hz, 1H), 8.41 (d, 
3
JHH = 8.2 Hz, 1H), 8.49 (d, 
3
JHH = 8.4 Hz, 1H), 9.33 (d, 
3
JHH = 5.7 Hz, 1H), 9.68 (d, 
3
JHH = 
5.7 Hz, 1H). 
13
C NMR (CD2Cl2, ppm) δ: 123.6, 124.2, 124.3, 124.4, 127.5, 127.6, 127.7, 
128.0, 138.8, 139.4, 139.9, 140.0, 147.9, 151.9, 153.5, 154.8(q), 155.3, 156.3(q), 156.8(q), 
156.8(q), 198.77(q). MS: m/z 477 [M
+
]. IR: CO 1953 cm
–1
(ATR), 1965 cm
–1
 (KBr). 
Synthesis of cis-[Ru(bpy)2(CO)(H2O)](ClO4)2, [2(ClO4)2]. Cis-
[Ru(bpy)2(CO)(H2O)](ClO4)2, was prepared with a slightly modified literature method 
previously used for ruthenium aqua analogues.
17
 The structure of 2 was confirmed by 
1
H 
NMR and IR. Cis-[Ru(bpy)2(CO)Cl]ClO4 (0.55 g, 1.1 mmol) and AgClO4 (0.48 g, 2.3 mmol) 
were added to 100 mL of 2:1 acetone/water. The solution was stirred and heated at reflux for 
2 hours under N2, and then allowed to cool to room temperature. The solution was filtered on 
a sintered-glass filter to remove the AgCl formed during the reaction, and the filtrate was 
reduced in volume by rotary evaporation. The remaining solution was added to a saturated 
solution of NaClO4 and a yellow precipitate (complex 2) formed. The flask was placed in a 
refrigerator at 277 K for 30 min, and then the yellow product was filtered off and washed 
with aliquots of cold water (0.53 g, 0.8 mmol, 74% yield). 
1
H NMR (D2O, ppm) δ: 7.22 (t, 
3
JHH = 6.2 Hz, 1H), 7.44 (dd, 
3
JHH = 5.6 Hz, 1H), 7.59 (d, 
3
JHH = 5.6 Hz, 1H), 7.64 (d, 
3
JHH = 
4.7 Hz, 1H), 7.82 (t, 
3
JHH = 5.9 Hz, 1H), 7.91 (t, 
3
JHH = 6.2 Hz, 1H), 7.99 (t, 
3
JHH = 8.5 Hz, 
1H), 8.17 (t, 
3
JHH = 8.0 Hz, 1H), 8.28 (t, 
3
JHH = 8.0 Hz, 1H), 8.37 (d, 
3
JHH = 7.8 Hz, 1H), 8.39 
(t, 
3
JHH = 7.8 Hz, 1H), 8.53 (d, 
3
JHH = 8.2 Hz, 1H), 8.56 (d, 
3
JHH = 8.5 Hz, 1H), 8.59 (d, 
3
JHH = 
8.2 Hz, 1H), 8.92 (d, 
3
JHH = 5.9 Hz, 1H), 9.49 (d, 
3
JHH = 4.7 Hz, 1H). IR: CO 1966 cm
–
1
(ATR), 1992 cm
–1
 (KBr) and OH 3070 cm
–1
(ATR), 3087 cm
–1
 (KBr). 
UV-visible spectroscopy. UV-visible electronic absorption spectra were recorded on a 
Varian Cary 300 UV-visible spectrophotometer in 1 cm path-length cuvettes. Data were 
processed with Microcal Origin 8.0. 
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NMR spectroscopy. NMR spectra were recorded on a Bruker DMX 600 spectrometer (
1
H 
operating frequency 600 MHz). 
1
H NMR spectra were recorded in D2O, dioxane was added 
as internal reference (δ = 3.75 ppm) and 5% deuterated dmso to increase the solubility of the 
complex. The 
1
H-
1
H TOCSY and 
1
H-
1
H NOESY (phase sensitive) 2D NMR spectra were 
recorded using standard pulse sequences. The TOCSY mixing time was 60 ms, the NOESY 
mixing time was 0.50 s. 
Infrared spectroscopy. IR spectra were recorded both as a KBr pellet using a Bruker 
Equinox 55 FT-IR spectrophotometer and as powder-ATR using a Thermo-Nicolet 670 FT-
IR spectrophotometer with a resolution of 1 cm
–1
 and an accumulation of 64 scans. 
Electrospray ionization high resolution mass spectrometry (ESI-HR-MS). HR-MS data 
were obtained using a Bruker MicrOTOF mass spectrometer equipped with an electrospray 
source operating in positive ion mode (ESI+). The m/z values reported (scan range: 50 1500 
Da) are the strongest in the isotope envelope, and formulae were confirmed by matching 
isotope patterns with simulated ones generated with Bruker Daltonics DataAnalysis V4.0. 
Photochemistry. The light source used was a LZC-ICH2 photoreactor (Luzchem Research 
Inc.) equipped with a temperature controller and a 16 LZC-VIS UV-visible light lamps 
(Sylvania cool white,  = 250–700 nm) with no other sources of light filtration. The 
temperature was controlled to 310 K unless otherwise stated. The power levels were 
monitored and assessed using the appropriate probe window, calibrated against an OAI-306 
UV power meter from Optical Associates, Inc.; the delivered radiation dose (ca. 1 J/cm
2
 h) is 
defined as irradiance (P, W cm
–2
) × time (s). HR-MS and NMR spectra in a water/dmso 
(95%/5%) mixture were then recorded soon after irradiation at different time delays. 
Computational Details. All calculations were performed with the Gaussian 03 (G03) 
program,
18
 employing the DFT method. The ground state geometry optimization was 
performed in the gas phase at two different levels of theory: PBE1PBE
19
/LanL2DZ/6-31G** 
(BS1 level) and B3LYP
20
/LanL2DZ/6-31G** (BS2 level); the LanL2DZ
21
 basis set and 
effective core potential was employed for the Ru atom, while the 6-31G**
22
 basis set was 
used for all other atoms. The lowest-lying triplet state geometry was optimized in the gas 
phase using the unrestricted Kohn-Sham formalism (UKS).
23
 The nature of all stationary 
points was confirmed by normal-mode analysis. 
6 
 
Thirty-two singlet electronic transitions were calculated by TDDFT,
24
 employing the ground 
state structures optimized at the BS1 and BS2 level and including the solvent effect using the 
CPCM
25
 method, with water as solvent. For the TDDFT calculations, either the 6-31G** 
(BS1a and BS2a) and the 6-311G**
22
 (BS1b and BS2b) basis sets were employed (6-31G** 
and 6-311G** were used for the Cl, O, N, C, H atoms, while the LanL2DZ was used for Ru). 
The program GaussSum 1.05
26
 was used to simulate the electronic spectra of the ruthenium 
complex and to visualize the singlet excited state transitions as electron density difference 
maps (EDDMs).
27
 
X-ray Absorption Spectroscopy (XAS). EXAFS spectra were acquired on the Dutch 
beamline at ESRF (BM26 – Dubble)28 at the Ru K-edge (22117 eV) in transmission 
geometry, using ionization chambers and a fixed-exit monochromator mounting a pair of Si 
311 crystals. Energy scans were performed in the range 21690–23350 eV, corresponding to a 
maximum extension of the EXAFS signal in the k-space of 18 Å
–1
. In the edge region 
(XANES), spectra were sampled with 0.5 eV/point and integration time of 5 s/point; in the 
EXAFS region the sampling was constant at k = 0.05 Å
–1
 and the integration time linearly 
increased from 4 to 10 s/point from 3 to 18 Å
–1
. Aqueous solutions (10 mM) of 1 and 2 were 
loaded in cells with different thickness (up to 1.5 cm) in order to obtain a total absorption 
coefficient between one and two and an edge step close to one. A minimum of five energy 
scans were acquired for each sample to achieve high signal-to-noise ratio, and averaged after 
(k) extraction.
29
 EXAFS analyses were conducted in the 4–18 Å–1 range, starting from 
structures optimized by DFT calculations. Fits were performed in k-space, without Fourier 
filtering, in order to avoid mathematical artifacts. EXAFS data analysis was performed using 
the ESTRA and FITEXA software,
30
 which is an evolution of the Frascati code.
31
 The code 
exploits the minimization routines of the MINUIT code
32
. Phase and amplitude functions 
were calculated by FEFF 8.2 code
33
 using the structures optimized by DFT calculations as 
input. Previous work on similar Ru(II) complexes
11c,34
 already proved the validity of the 
phases and amplitudes computed by such approach. 
Cell lines. Analyses were carried out using a human urinary bladder carcinoma (5637), a lung 
carcinoma (A-427) and a pancreas carcinoma (DAN-G) cell lines (German Collection of 
Microorganisms and Cell Cultures, DSMZ, Braunschweig, Germany). Cells were grown in 
medium containing 90% RPMI 1640 medium (Sigma, Taufenkirchen, Germany) and 10% 
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FCS (Sigma), and supplemented with penicillin G (30 mg/L)/streptomycin (40 mg/L). Cells 
were kept at 310 K in a humidified atmosphere of 5% CO2. 
Antiproliferative activity. Cytotoxicity of 1 was determined by the crystal violet assay.
35
 
Cells were seeded in 96-well microtiter plates in 100 µL medium at a density of 1000 
cells/well and left to adhere overnight. After washing with PBS, the cells were treated with 
100 µL of 20 µM solution of 1 in medium (maximum dmso concentration of 0.1%, v/v) and 
incubated for 1 h. After this time, cells were either irradiated for 30 min with UV light λ = 
366 nm or kept in the dark. Luzchem Expo panels (Luzchem Reasearch Inc., Ontario, 
Canada) were used for UV irradiation. The two Expo panels were accommodated with 5 
fluorescent lamps each. Lower UV light was cut off by a filter. The light source was 
positioned 25 cm away from the samples giving an intensity of 0.12 W/cm
2
. Medium removal 
occurred after 6 hours and the cell survival was determined by using the crystal violet assay. 
Experiments were performed in triplicate. 
 
Results and Discussion 
Structural and electronic properties. The X-ray absorption spectra of the chlorido complex 
1 and aqua complex 2 were acquired to investigate the solution structures of the complexes 
and are shown in Figure 1. Data for both complexes could be fitted with structural parameters 
that are consistent with the computed structures, and in the case of 1 also with the crystal 
structure. 
XANES (X-ray Absorption Near-Edge Structure) is sensitive to electronic properties, 
geometry and local structure surrounding the absorber atom (ruthenium). The similarity of 
the two XANES spectra suggests that the substitution of a Cl ligand with a water molecule 
leaves almost unchanged the local coordination and geometry of all remaining ligands around 
the metal center. Moreover, the lack of any detectable shift in the absorption edge energy 
position confirms that ruthenium has the same oxidation state and the same electronic 
configuration both in 1 and 2. 
The EXAFS (Extended X-ray Absorption Fine Structure) signals and the corresponding fit 
curves for 1 and 2 are reported in Figure 2. Figure 2A reports k
3
-weighted EXAFS signal 
(circles) and fit curves (solid lines). Figures 2B and 2C report the moduli and the imaginary 
parts of the corresponding Fourier transforms (FT), which represent the radial distribution 
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function centered on the absorber atom. Each peak in the FT corresponds to an average length 
(after phase correction) of a single scattering path, or to the convolution of more than one 
path. The first peak (around 1.7 Å) is related to Ru–N distances and to the Ru–C distance 
involving the CO ligand (Ru–CCO); the second peak at ca. 2 Å, present only in the spectrum 
of 1, is associated to the Ru–Cl distance. Conversely, in the spectrum of 2, the peak 
associated to the Ru–O distance involving the H2O ligand is not visible because it is 
overlapped with the first peak, due to the small difference between the Ru–N and Ru–O bond 
lengths. Additional peaks at higher R values (2.5–3 Å, uncorrected for phase shift) are related 
to the Ru–Cbpy distances, plus single scattering (SS) of the oxygen atom of the CO ligand and 
multiple scattering (MS) contributions of the CO ligand (two-body Ru–O–CCO, and three-
body Ru–CCO–O–CCO–Ru). Additional MS paths involving the bpy carbons (three bodies 
Ru–Cbpy–N) were found to have a relevant contribution to the EXAFS signal and were 
included in the fits. Contributions beyond 3 Å were not fitted because they do not bring 
relevant structural information. Moreover, since in the range 3–4.7 Å there are several MS 
contributions overlapping, it is difficult to obtain reliable fits. The signal beyond 4.7 Å is 
negligible. 
In both k- (Figure 2A) and R-spaces (Figure 2B and 2C), there is a good correspondence 
between the experimental and theoretical curves. In the EXAFS spectrum of 2, the loss of the 
Ru–Cl contribution (substitution of Cl with H2O) results in an increase of the first shell 
signal, due to the fact that Ru–Cl and Ru–O paths are out of phase in a large region of the k-
space.
36
 This also has little effect on the higher shell signal (2.2–3.5 Å), as well evidenced by 
the imaginary parts (Figure 2C) of both spectra. Such EXAFS features confirm the XANES 
observation that the ligand substitution hardly affects both distances and geometries of the 
CO and bpy ligands. 
The data for complex 1 were fitted by refining thirteen independent parameters and 
for complex 2 with eleven. All paths have the same amplitude reduction (S0
2
) and energy 
shift ( E) factors. For complex 2 Ru–OH2O and Ru–N paths were fitted using the same 
distance parameters and Debye-Waller factors, because the difference in the length is below 
the resolution limit and EXAFS chemical selectivity is limited to z = 4.
37
 
Refined structural parameters obtained from the EXAFS fit are reported in Table 1. In 
cases where the higher shell distances is due to metal carbonyls only, also the C–O distance 
of the CO molecule can be determined with EXAFS.
38
 In the present case and in others 
successfully solved,
39
 the co-presence of scattering contributions involving the carbon atoms 
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of the bpy ligands imposes a constraint on the C–O distance to the expected value in the gas 
phase (1.128 Å). 
Structural parameters from DFT were compared to X-ray diffraction (XRD) data for complex 
1 only,
16a
 while comparison with EXAFS data was performed for both complexes (Table 2). 
DFT bond distances and angles are in good agreement with XRD data, the only exception 
being the N2–Ru–Cl angle which is strongly distorted in the XRD structure due to the crystal 
packing.
16a
 EXAFS data are also in good agreement with both XRD data and DFT 
calculations. Considering the lower resolution of EXAFS technique, the three approaches 
agree on values of the Ru–CCO, Ru–N, Ru–Cl and Ru–OH2O distances, to within 0.01, 0.02, 
0.01 and 0.02 Å, respectively. For the Ru–N distance, the EXAFS value was compared 
with the average distances of XRD and DFT approaches (<Ru–N>XRD = 2.111 Å and <Ru–
N>DFT = 2.0965 Å, for complex 1; <Ru–N>DFT = 2.0945 Å for complex 2). In all cases the 
CO ligand binds almost linearly to Ru(II). No significant difference is observed between the 
two functionals employed, nevertheless the PBE1PBE functional gives slightly better bond 
distance values (Supporting Information). In the lowest-lying triplet state, 1 shows a distorted 
geometry where two Ru–Nbpy distances are elongated of 0.23 and 0.29 Å compared to the 
ground-state geometry. Also in the case of 2, DFT calculations (<Ru–N/OH2O> = 2.118 Å) 
seem to reproduce well the experimental values obtained by EXAFS (2.102 Å). 
DFT calculations and photophysical properties. The most significant frontier orbitals of 1 
are shown in Figure 3. The HOMO is localized on the Ru–Cl bond (Ru d orbital and Cl p 
orbital), while the LUMO and LUMO+1 are almost degenerate and centered on the two 
different bpy ligands. LUMO+6 is a strong *-antibonding orbital and plays a key role in the 
photochemical properties of the complex. The lowest-lying triplet of 1 shows two SOMOs 
with antibonding character (Supporting Information); the lowest-SOMO is a * Ru–Cl orbital 
and the highest-SOMO is a *-antibonding orbital resembling the LUMO+6 of the ground 
state geometry. The frontier orbitals of 2 in the ground state geometry are similar to the 
orbitals obtained for 1. 
Thirty-two singlet transitions were calculated by TDDFT to assign the UV-visible absorption 
spectrum of 1, employing the ground-state structures optimized at the BS1 and BS2 level. For 
each geometry and functional, either the 6-31G** or the 6-311G** basis set were used for the 
Cl, O, N, C, H atoms (while the LanL2DZ was employed for Ru). No significant difference 
was found between the calculations; only, a ca. 20-nm red-shift of the two lowest-energy 
10 
 
singlet transitions was observed when the B3LYP functional was used and when the 6-
311G** basis set was employed. 
Figure 4 shows the experimental spectrum for an aqueous solution and the singlet transitions 
calculated at the BS1b level (for the others see Supporting Information). The main absorption 
band (230–330 nm) contains two sets of singlet transitions. The first set has high oscillator 
strengths and shows a prevalent metal-to-ligand charge-transfer (MLCT) character; the 
second set is composed of transitions with major metal-centered (MC) character and lower 
oscillator strengths. The lowest-energy singlet transitions (> 340 nm) are all MLCT, except 
one which is MC (360 nm) and has a strongly dissociative character due to the contribution of 
LUMO+6. 
The lowest-lying triplet state geometry was calculated with the unrestricted Kohn-Sham 
method.
23
 The spin density surface and the SOMOs (Supporting Information) highlight the 
MC nature of this state, which is consistent with the lack of emission of 1 in several solvents 
and to its photochemical behaviour.
40
 
Photochemistry. As suggested by Tanaka et al.,
13
 when irradiated in aqueous solution 
complex 1 undergoes photolysis to form the aqua species cis-[Ru(bpy)2(CO)(H2O)]
2+
 (2). The 
1
H NMR spectrum in Figure 5 shows that 1 is completely converted into 2 after 3 h of 
irradiation with white light at ca. 1 J/cm
2
 h. During irradiation and conversion of 1 into 2, the 
pH of the solution changes from 7.3 to 5.3. Since the pKa of the Ru OH2/OH equilibrium for 
complex 2 is 8.3,
13
 the photo-hydrolysis product believed to prevail in solution is cis-
[Ru(bpy)2(CO)(H2O)]
2+
. Hydrolysis of the Ru–Cl bond occurs also in the dark, however the 
thermally-activated reaction is significantly slower compared to the photoinduced hydrolysis. 
In fact, at ca. 310 K twelve hours are required to reach a 50% conversion of 1 (data not 
shown), while under irradiation the reaction is complete after three hours. Significantly, the 
1
H NMR spectra of the reaction products obtained by light- and thermal-activation are 
identical, confirming that in both cases 2 is formed. 
The aromatic region of the 
1
H NMR spectrum shows all the resonances from the non-
equivalent sixteen protons of the two bpy ligands. The two lowest-field doublets can be 
assigned to the ortho-protons of the (bpy) pyridine rings trans to each other. This assignment 
is based on data for [Os(bpy)2(CO)(X)]
+
 analogues (where X = Cl, CF3SO3 and H).
41
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ESI-HR-MS analysis of the irradiated samples of 1 in solution (95% H2O/5% dmso) 
confirmed 2 as a major photoproduct, yielding the molecular formula C21H17N4O2Ru
+
 for the 
m/z = 459 ion (calcd.: 459.0395, found: 459.0398) consistent with [M  H]
+
. The m/z = 477 
ion corresponding to remaining complex 1 was also identified (calcd.: 477.0107, found: 
477.0053). In addition, a m/z = 260 ion corresponding with the molecular formula 
C23H22N4O2RuS
2+
 (calcd.: 260.0248, found: 260.0288) was assigned to the adduct 
[Ru(bpy)2(CO)(dmso)]
2+
, which had been previously detected in small quantities by 
1
H NMR 
when 1 was irradiated for a prolonged period. 
Irradiation of 1 in the presence of 9-ethylguanine, 9-EtG, (ca. 1:1.5 ratio, pH = 6.1) was 
monitored by 
1
H NMR. Complex 2 is the major photoproduct, however, formation of Ru-
guanine adducts was observed as well (Figure 6). At least two different types of metal-
nucleobase adduct are observed as revealed by the presence of two new singlet resonances 
(blue arrows in Figure 6) at 7.04 and 6.77 ppm. Both these signals can be assigned to the H8 
of 9-EtG of two different Ru-guanine adducts, which are present at 16% and 25% in 
comparison to 2, as determined from the 
1
H NMR peak areas. The shift of the H8 signal for 
these two species is consistent with the shielding effect induced by the ring current of the bpy 
ligands.
8d
 Using 2D 
1
H-
1
H TOCSY and NOESY NMR data, it was possible to confirm that 
the singlet at 6.77 ppm corresponds to a metal-nucleobase species. In particular, a crosspeak 
between the H8 of 9-EtG and a bpy proton was observed in the NOESY spectrum. 
Interestingly, when the same solution was left in the dark at 310 K, the 
1
H NMR spectrum did 
not show any formation of Ru-9-EtG adducts, even after 24 h. The presence of two adducts 
can be ascribed to the loss of CO, possibly caused by prolonged irradiation of the 
photoproduct 2. Binding through the N1 of 9-EtG can be ruled out due to steric hindrance 
(from modelling, not shown). In particular, the singlet at 6.77 can be assigned to the H8 
proton of cis-[Ru(bpy)2Cl(9-EtG)]
+
, a species previously isolated and crystallized after the 
hydrolysis of cis-[Ru(bpy)2Cl2] in the presence of 9-EtG.
8d
 Hence it appears that released Cl
-
 
ions can re-coordinate after CO displacement. 
When the irradiated solution of 1 and 9-EtG was analyzed by ESI-HR-MS, a major peak was 
observed in the spectrum corresponding to complex 2 (calcd.: 459.0395, found: 459.0421). 
Another major ion (m/z = 296) yielded the molecular formula C27H25N9ORu
2+ 
(calcd.: 
296.5611, found: 296.5583), consistent with the species {[Ru(bpy)2(9-EtG)]}
2+
, therefore 
confirming ruthenation of the nucleobase. 
12 
 
Reaction of complex 1 with 9-ethyladenine (9-EtA) was investigated both in the dark (pH = 
6.5) and under irradiation. Formation of adducts between the metal complex and the adenine 
derivative were not observed by 
1
H NMR even after six hours of irradiation, while HR-MS 
data suggested possible formation of a very small amount of a Ru-9-EtA adduct showing a 
m/z = 288 ion, attributable to {[Ru(bpy)2(CO)(9-EtA)]}
2+
 (C28H25N9ORu
2+
; calcd.: 288.5636, 
found: 288.5642).  
In view of the finding that light can activate complex 1 toward binding to guanine, a potential 
nucleobase target in DNA, we investigated the photocytotoxicity of the complex towards 
three different human carcinoma cell lines. 
Antiproliferative activity. Complex 1 was found to be non-toxic to human urinary bladder 
(5637), lung (A-427) and pancreatic (DAN-G) carcinoma cells in the dark or after 30 min UV 
irradiation (  = 366 nm) of cells which had been incubated with 20 µM of 1 for 1 h. The 
complex did not show any cytotoxic effect at the tested concentration. We can only speculate 
as to the reasons for this. The complex is positively charged and cell uptake could be low for 
the incubation time used in the current protocol (1 h). It is possible that even though 1 should 
be reactive towards DNA when photoactivated, it does not reach DNA. Alternatively, if DNA 
lesions are formed, then perhaps they are readily excised or repaired, especially if 
monodentate rather than bidentate adducts are formed. In view of the evidence of the 
interaction between complex 1 and 9-EtG, and the possibility that DNA adducts might be 
stable, in future studies it might be worthwhile to investigate cell uptake after longer 
incubation times. 
 
Conclusions 
We have shown that the complex cis-[Ru(bpy)2(CO)Cl]
+
 (1), already known for its 
photocatalytic properties,
13,14
 can release a Cl
–
 ligand and bind to the nucleobase analogue 9-
EtG when irradiated with visible light. NMR and HR-MS confirmed the formation of Ru-9-
EtG adducts. Interestingly, in the dark there is no ruthenation of this DNA base although 
formation of the product cis-[Ru(bpy)2(CO)(H2O)]
2+
 (2) occurs. This suggests that further 
photoactivation of the aqua species is required for binding to 9-EtG. 
13 
 
For both complexes 1 and 2, Ru K-edge EXAFS data were in good agreement with both 
XRD data and DFT calculations. The TDDFT calculations show that LUMO+6 is a strong 
*-antibonding orbital and plays a key role in the photochemical properties of the complex. 
The lowest-lying triplet of 1 shows two SOMOs with metal-centered antibonding character. 
The presence of this low-lying dissociative 
3
MC state can be associated with the light-
induced release of a Cl ligand and subsequent coordination of a solvent molecule. 
Although complex 1 showed no cytotoxic activity towards the human cancer cells used in this 
study at a concentration of 20 µM, its ability to bind to nucleobases in the presence of light 
suggests that this class of complexes might provide valuable leads for new photoactivatable 
antitumor ruthenium complexes. 
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Table 1. Coordination numbers (c.n.), atomic distances (R), and Debye-Waller factors ( ) 
obtained from EXAFS refinements for 1 and 2. The c.n. were kept fixed to theoretical values. 
A common 
2
 parameter for Ru–CCO and Ru–N/OH2O, and for Ru–Cbpy paths was employed. 
Only single scattering paths are reported. Numbers in parenthesis represent the error in the 
last digit. Also reported are the reduced 2, the <x,y> are the highest correlations between 
parameters x and y (all the other being below 0.50 in absolute value). 
 
 1 2 
Path c.n. R Å  10–3 Å  c.n. R Å  10–3 Å  
Ru–CCO 1 1.874(8) 
2.2(3) 
1 1.865(9) 
2.8(4) 
Ru–N/OH2O 4 2.076(6) 5 2.102(6) 
Ru–Cl 1 2.416(7) 3.2(6) – – – 
Ru–C1(bpy) 
Ru–C2(bpy) 
4 
4 
2.91(1) 
3.03(1) 
1.6(9) 
4 
4 
2.88(1) 
2.96(1) 
1.1(9) 
Ru–OCO 1 3.00(1) 1.1(9) 1 2.99(1) 3.1(9) 
E (eV) –1(1) 2(1) 
S0
2
 0.74(6) 0.76(6) 
2
 3.0 4.3 
S0
2
, Ru–C(CO)  0.84 0.74 
E,Ru–N/OH2O  0.81 0.68 
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Table 2. XRD, EXAFS and DFT structural parameters for 1 and 2. For the EXAFS data, 
where R values are in merged cells, a single path with higher degeneration has been used in 
the fitting process. 
 
1 2 
XRD
a
 EXAFS DFT - GS
b
 DFT - LL
c
 EXAFS DFT - GS
b
 
Bond distances (Å)       
C−O 1.122 1.128d 1.148 1.146 1.128d 1.145 
Ru−CCO 1.861 1.874(8) 1.877 1.888 1.865(9) 1.894 
Ru−N1 2.097 
2.076(6) 
2.088 2.380 
2.102(6) 
2.087 
Ru−N2e 2.066 2.086 2.242 2.054 
Ru−N3f 2.177 2.129 2.144 2.132 
Ru−N4 2.104 2.083 2.317 2.105 
Ru−OH2O − − − − 2.210 
Ru−Cl 2.396 2.416(7) 2.440 2.411 − − 
Angles (degrees)       
Ru−C−O 174.8 180g 177.9 178.6 180g 178.8 
N2−Ru−Cl 155.3 
 
172.4 164.7  171.3 
N1−Ru−N4 167.6 173.3 161.2  172.6 
N3−Ru−C 176.5 172.6 174.7  174.9 
N1−Ru−N2 78.7 78.1 69.7  78.9 
N3−Ru−N4 76.9 77.8 74.1  77.6 
N1−C−C−N2 2.7 0.9 11.5  1.1 
N3−C−C−N4 -6.4 < 0.1 14.3  1.4 
a From reference 16a 
b GS = ground state 
c LL = lowest-lying triplet state 
d C−O distance of the CO molecule has been fixed to the value in the gas phase 
e N trans to Cl or O 
f N trans to CO 
g This angle was fixed at 180° in EXAFS refinements 
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Figure 1. XANES and EXAFS X-ray absorption spectra of 1 (red line) and 2 (blue line). 
Inset: structural scheme used to construct SS and MS paths for the EXAFS data analysis. 
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Figure 2. (A) k
3
-weighted EXAFS signals (circles) of complexes 1 (red) and 2 (blue), and 
corresponding best fits (solid lines). (B) k
3
-weighted, phase uncorrected, Fourier transform 
moduli (k-range 4–18 Å–1) of the EXAFS signals of fit curves reported in (A). (C) Imaginary 
parts of the FTs reported in (B). See Supporting information for the k
3
-FT spectra plotted up 
to 5 Å. 
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Figure 3. Selected molecular orbitals for complex 1. 
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Figure 4. Experimental absorption spectrum (black line) and calculated singlet excited state 
transitions (blue vertical bars) of 1 in H2O. The vertical bar height is the oscillator strength. 
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Figure 5. 
1H ΝΜR spectrum of 1 in D2O/dmso-d6 (95%/5%) solution in the dark (sixteen 
non-equivalent bpy protons, upper spectrum) and after 3 h of irradiation with white light 
(lower spectrum), showing the formation of the photoproduct 2 (sixteen non-equivalent bpy 
protons). 
22 
 
 
 
Figure 6. 
1H ΝΜR spectrum of 1 + 9-EtG (1:1.5 ratio) in D2O/dmso-d6 (95%/5%) solution in 
the dark (upper) and after 3 h of irradiation with white light (lower). In the lower spectrum, 
the ● labels indicate the bpy resonances of cis-[Ru(bpy)2(CO)(H2O)]
2+
 (2), the blue arrows 
indicate the 9-Et-G H8 resonances of two different metal-nucleobase adducts; a full 
assignment of the bpy resonances to specific adducts was not attempted due to peak overlap. 
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EXAFS, DFT, light-induced nucleobase binding and cytotoxicity of the 
photoactive complex cis-[Ru(bpy)2(CO)Cl]
+
  
 
Luca Salassa, Tiziana Ruiu, Claudio Garino, Ana M. Pizarro, Fabrizio Bardelli,
 
Diego 
Gianolio, Aron Westendorf, Patrick J. Bednarski, Carlo Lamberti, Roberto Gobetto,* and 
Peter J. Sadler*
 
 
Visible light (white) irradiation of aqueous solutions of cis-[Ru(bpy)2(CO)Cl]
+
 (1) at 310 K 
induced release of the Cl
-
 ligand and photoaquation giving cis-[Ru(bpy)2(CO)(H2O)]
2+
 (2); 
the solution structures of 1 and 2
 
were obtained by EXAFS, and DFT calculations provided 
insights into the mechanism of photoactivation of the chloride complex. Although 
photoinduced formation of 9-ethylguanine (9-EtG) nucleobase adducts by 1 was observed, 
the complex was not phototoxic to cancer cells.  
 
